Document 0030
 DOCN  M95B0030
 TI    Heterologous HIV-2 challenge of rhesus monkeys immunized with
       recombinant vaccinia viruses and purified recombinant HIV-2 proteins.
 DT    9511
 AU    Vogt G; le Grand R; Vaslin B; Boussin F; Auboyer MH; Riviere Y; Putkonen
       P; Sonigo P; Kieny MP; Girard M; et al; Laboratoire de Neuropathologie
       experimentale et Neurovirologie,; CRSSA, DSV, DPTE, CEA, Fontenay Aux
       Roses, France.
 SO    Vaccine. 1995 Feb;13(2):202-8. Unique Identifier : AIDSLINE MED/95351032
 AB    In an attempt to analyse the role of anti-envelope immunity in the
       protection of rhesus monkeys against an HIV-2 intravenous challenge,
       rhesus macaques were immunized twice with recombinant HIV-2 ROD vaccinia
       viruses (10(8) p.f.u. each) at days 0 and 30, followed by booster
       injections of purified HIV-2 proteins at months 8, 9, 15 and 27. One
       group of five macaques was immunized with the Gag, Pol, Vif and Nef
       antigens, whereas a second group received the same antigens with the
       addition of HIV-2 Env protein. Eight months after the last boost, the
       animals were challenged by intravenous injection of 100 AID50 of a
       monkey PBMC-grown stock of HIV-2 SBL. None of the animals was protected
       in spite of high humoral immune responses on day of challenge as
       determined by ELISA and Western Blot assays.
 DE    Animal  Antibodies, Viral/BIOSYNTHESIS  AIDS
       Vaccines/IMMUNOLOGY/*PHARMACOLOGY  Base Sequence  Gene Products,
       env/IMMUNOLOGY  HIV Antigens/*IMMUNOLOGY  HIV-2/GENETICS/*IMMUNOLOGY
       Macaca mulatta  Molecular Sequence Data  Support, Non-U.S. Gov't
       Vaccines, Synthetic/PHARMACOLOGY  Vaccinia Virus/*IMMUNOLOGY  Viral
       Vaccines/IMMUNOLOGY/*PHARMACOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).